Dabrafenib is a BRAF V600 inhibitor approved for metastatic melanoma in 2013, after it was shown to significantly improve PFS over dacarbazine in patients with a BRAF V600 mutation and untreated metastatic disease [32]. This evidence concerns the gene BRAF and metastatic neoplasm.